This is a study of an investigational drug called YL201 as a possible treatment for advanced solid tumors. YL201 is thought to work by interrupting DNA replication in cancer cells, via focused delivery of the cytotoxic agent to the cancer cell. YL201 has shown some anti-cancer effects against cancer cells in the laboratory and in experimental animals. The main purpose of this study is to learn how safe the study drug and how well the study drug works.
Thank you for your interest, but this study will start enrolling soon.
United States (Nationwide)
Shetal Patel
LCCC - Clinical Trials
Clinical or Medical
Interventional
Cancer (Head and Neck, Lung)
24-3022
Copyright © 2013-2022 The NC TraCS Institute, the integrated home of the NIH Clinical and Translational Science Awards (CTSA) Program at UNC-CH. This website is made possible by CTSA Grant UL1TR002489 and the National Center for Advancing Translational Sciences.
Questions?
